ACAT1 and neurodegenerative disease: Recent studies have further suggested repurposing ACAT inhibitors, traditionally developed for cardiovascular diseases, for treating neurodegenerative diseases due to their role in altering lipid metabolism [19,26,28,29,38,39,40,41,42,43,44].